)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Gubra
Gubra (GUBRA) investor relations material
Gubra Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary19 Jun, 2026
Strategic positioning and business model
Operates as a disease-agnostic techbio with deep peptide and preclinical expertise, structured into Biotech, CRO, and Ventures units for integrated value creation.
Biotech drives R&D and pipeline strategy, CRO provides foundational revenue, and Ventures accelerates value through external capital and new company creation.
Shared scientific core enables faster pipeline progression, broader portfolio, and multiple monetization paths.
Pipeline and clinical progress
Early clinical pipeline includes multiple obesity-focused assets, with several expected to enter Phase 2 in 2026.
ABBV-295 (amylin analog) and BI 3034701 (triple agonist) are out-licensed and advancing to Phase 2, showing strong weight loss and safety profiles.
GUB-UCN2, an internal program, targets muscle preservation and is set for Phase 1/2a trial in H2 2026.
Innovation and technology platforms
AI-driven StreamLine platform enables rapid peptide discovery, delivering multiple assets with high novelty and patentability.
Focus on muscle-preserving therapies and combination treatments aligns with shifting obesity treatment paradigms.
Advanced 3D imaging and AI quantification support preclinical validation and muscle growth analysis.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gubra
- CRO revenue and EBIT margin surged in 2024, with strong clinical and partnership progress.GUBRA
Q4 20249 Jul 2026 - Exclusive global rights and $350M upfront for novel obesity drug in Phase 1 trials.GUBRAPartnership9 Jul 2026
- Biotech revenue surged, pipeline assets advanced, and CRO grew sequentially despite market headwinds.GUBRAQ1 202612 May 2026
- Biotech revenue surged, clinical pipeline advanced, but CRO outlook and margins were trimmed.GUBRAQ1 20266 May 2026
- USD 2.2bn AbbVie deal and strong GUBamy data drive pipeline amid Q1 revenue decline.GUBRAQ1 202523 Apr 2026
- Record financials, landmark AbbVie deal, and pipeline expansion drive future growth.GUBRAInvestor presentation20 Apr 2026
- Record revenue and pipeline progress highlight strong growth and innovation in 2025.GUBRAInvestor presentation30 Mar 2026
- Record revenue and profit in 2025, fueled by AbbVie deal and pipeline progress; CRO recovery expected.GUBRAQ4 202527 Feb 2026
- Record revenue and profit in 2025, led by AbbVie deal and strong Biotech performance.GUBRAQ4 202527 Feb 2026
Next Gubra earnings date
Q2 202620 Aug, 2026
Gubra
Next Gubra earnings date
Q2 202620 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage